查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1522994

雙極性情感障礙治療藥物市場報告：2030 年趨勢、預測與競爭分析

Bipolar Disorder and Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

雙相情感障礙治療藥物的趨勢和預測

預計 2024 年至 2030 年，全球雙相情感障礙治療藥物市場將以 3.7% 的複合年成長率成長。該市場的主要促進因素是人們對心理健康的認知不斷提高以及雙相情感障礙盛行率的上升。全球雙極性情感障礙藥物市場的未來看起來充滿希望，口服和腸胃外藥物市場充滿機會。

按細分市場分類的雙相情感障礙治療藥物趨勢

本研究按藥物類別、給藥途徑、作用機制和區域提供雙極性情感疾患藥物的全球市場預測。

雙極性情感障礙藥物市場洞察

Lucintel 預測，由於精神病症狀病例的增加，抗精神病藥物在預測期內仍將是最大的細分市場。

由於口服藥物的給藥靈活性和成本效益，其仍將是該市場的最大細分市場。

由於雙極性情感障礙盛行率不斷上升，北美在預測期內仍將是最大的地區。

常問問題

Q1.市場成長預測是多少：

A1. 2024年至2030年，全球雙極性情感疾患治療藥物市場預計將以3.7%的複合年成長率成長。

Q2. 影響市場成長的關鍵促進因素是：

A2. 這個市場的主要驅動力是心理健康意識的提高和躁鬱症盛行率的上升。

Q3.市場的主要細分市場是：

A3. 雙極性情感障礙藥物市場前景廣闊，口服和注射藥物市場都有機會。

Q4.市場的主要企業是：

A4. 生產雙極性情感疾患治療藥物的主要企業如下：

  • GlaxoSmithKline
  • Pfizer
  • Eli Lily
  • AbbVie
  • Otsuka Holdings
  • AstraZeneca
  • Novartis

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預計，由於精神病症狀病例數量不斷增加，抗精神病藥物在預測期內仍將是其最大的細分市場。

Q6.未來五年預計哪些地區的市場成長最大？

A6. 由於雙極性情感疾患的盛行率不斷上升，北美在預測期內仍將是最大的地區。

Q7. 可以客製化報告嗎？

A7。

目錄

第1章執行摘要

第2章全球雙極性情感疾患治療藥物市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 雙相情感障礙治療藥物的全球市場趨勢（2018-2023）和預測（2024-2030）
  • 按藥物類別分類的全球雙極性情感障礙治療藥物市場
    • 情緒穩定劑
    • 抗驚厥藥
    • 抗精神病藥
    • 抗憂鬱症
    • 抗焦慮藥
  • 途徑分類的全球雙極性情感障礙治療藥物市場
    • 口腔醫學
    • 腸外藥物
    • 其他
  • 按作用機轉分類的雙極性情感疾患治療藥物的全球市場
    • 選擇性血清素再回收抑制劑
    • 正腎上腺素再回收抑制劑
    • 三環抗憂鬱藥物
    • BETA阻斷劑
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球雙極性情感障礙治療藥物市場（按地區）
  • 北美雙相情感障礙藥物市場
  • 歐洲雙極性情感障礙藥物市場
  • 亞太雙向情感障礙藥物市場
  • 其他區域雙極性情感障礙治療藥物市場

第5章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球雙極性情感疾患治療藥物市場成長機會（依藥物類別）
    • 按給藥途徑的全球雙相情感障礙治療藥物市場成長機會
    • 全球雙極性情感障礙治療藥物市場成長機會（按作用機制）
    • 全球雙極性情感障礙治療藥物市場成長機會（按地區）
  • 全球雙相情感障礙藥物市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大雙極性情感障礙藥物市場的全球容量
    • 全球雙極性情感障礙藥物市場的合併、收購與合資企業
    • 認證和許可

第7章主要企業概況

  • GlaxoSmithKline
  • Pfizer
  • Eli Lily
  • AbbVie
  • Otsuka Holdings
  • AstraZeneca
  • Novartis
簡介目錄

Bipolar Disorder and Treatment Trends and Forecast

The future of the global bipolar disorder and treatment market looks promising with opportunities in the oral and parenteral markets. The global bipolar disorder and treatment market is expected to grow with a CAGR of 3.7% from 2024 to 2030. The major drivers for this market are rising awareness on mental health and rising prevalence of bipolar disorders.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Bipolar Disorder and Treatment by Segment

The study includes a forecast for the global bipolar disorder and treatment by drug class, route of administration, mechanism of action, and region.

Bipolar Disorder and Treatment Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Mood Stabilizer
  • Anticonvulsants
  • Anti-Psychotic Drugs
  • Anti-Depressant Drugs
  • Anti-Anxiety Drugs

Bipolar Disorder and Treatment Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Parenteral
  • Others

Bipolar Disorder and Treatment Market by Mechanism of Action [Shipment Analysis by Value from 2018 to 2030]:

  • Selective Serotonin Reuptake Inhibitor
  • Serotonin Norepinephrine Reuptake Inhibitor
  • Tricyclic Antidepressant Drug
  • Beta Blockers
  • Others

Bipolar Disorder and Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Bipolar Disorder and Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bipolar disorder and treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bipolar disorder and treatment companies profiled in this report include-

  • GlaxoSmithKline
  • Pfizer
  • Eli Lily
  • AbbVie
  • Otsuka Holdings
  • AstraZeneca
  • Novartis

Bipolar Disorder and Treatment Market Insights

Lucintel forecasts that anti-psychotic drug will remain the largest segment over the forecast period due to growing cases of psychotic symptoms.

Within this market, oral will remain the largest segment due to its enhanced dosing flexibility and cost-effectiveness.

North America will remain the largest region over the forecast period due to rising prevalence of bipolar disorders.

Features of the Global Bipolar Disorder and Treatment Market

Market Size Estimates: Bipolar disorder and treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Bipolar disorder and treatment market size by drug class, route of administration, mechanism of action, and region in terms of value ($B).

Regional Analysis: Bipolar disorder and treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug class, route of administration, mechanism of action, and regions for the bipolar disorder and treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bipolar disorder and treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for bipolar disorder and treatment market?

Answer: The global bipolar disorder and treatment market is expected to grow with a CAGR of 3.7% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the bipolar disorder and treatment market?

Answer: The major drivers for this market are rising awareness on mental health and rising prevalence of bipolar disorders.

Q3. What are the major segments for bipolar disorder and treatment market?

Answer: The future of the bipolar disorder and treatment market looks promising with opportunities in the oral and parenteral markets.

Q4. Who are the key bipolar disorder and treatment market companies?

Answer: Some of the key bipolar disorder and treatment companies are as follows:

  • GlaxoSmithKline
  • Pfizer
  • Eli Lily
  • AbbVie
  • Otsuka Holdings
  • AstraZeneca
  • Novartis

Q5. Which bipolar disorder and treatment market segment will be the largest in future?

Answer: Lucintel forecasts that anti-psychotic drug will remain the largest segment over the forecast period due to growing cases of psychotic symptoms.

Q6. In bipolar disorder and treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to rising prevalence of bipolar disorders.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the bipolar disorder and treatment market by drug class (mood stabilizer, anticonvulsants, anti-psychotic drugs, anti-depressant drugs, and anti-anxiety drugs), route of administration (oral, parenteral, and others), mechanism of action (selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, tricyclic antidepressant drug, beta blockers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Bipolar Disorder and Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Bipolar Disorder and Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Bipolar Disorder and Treatment Market by Drug Class
    • 3.3.1: Mood Stabilizer
    • 3.3.2: Anticonvulsants
    • 3.3.3: Anti-Psychotic Drugs
    • 3.3.4: Anti-Depressant Drugs
    • 3.3.5: Anti-Anxiety Drugs
  • 3.4: Global Bipolar Disorder and Treatment Market by Route of Administration
    • 3.4.1: Oral
    • 3.4.2: Parenteral
    • 3.4.3: Others
  • 3.5: Global Bipolar Disorder and Treatment Market by Mechanism of Action
    • 3.5.1: Selective Serotonin Reuptake Inhibitor
    • 3.5.2: Serotonin Norepinephrine Reuptake Inhibitor
    • 3.5.3: Tricyclic Antidepressant Drug
    • 3.5.4: Beta Blockers
    • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Bipolar Disorder and Treatment Market by Region
  • 4.2: North American Bipolar Disorder and Treatment Market
    • 4.2.1: North American Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
    • 4.2.2: North American Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
  • 4.3: European Bipolar Disorder and Treatment Market
    • 4.3.1: European Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
    • 4.3.2: European Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
  • 4.4: APAC Bipolar Disorder and Treatment Market
    • 4.4.1: APAC Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
    • 4.4.2: APAC Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
  • 4.5: ROW Bipolar Disorder and Treatment Market
    • 4.5.1: ROW Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
    • 4.5.2: ROW Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Mechanism of Action
    • 6.1.4: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Region
  • 6.2: Emerging Trends in the Global Bipolar Disorder and Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Bipolar Disorder and Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Bipolar Disorder and Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: GlaxoSmithKline
  • 7.2: Pfizer
  • 7.3: Eli Lily
  • 7.4: AbbVie
  • 7.5: Otsuka Holdings
  • 7.6: AstraZeneca
  • 7.7: Novartis